Pacira BioSciences Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Pacira BioSciences kazanç ve gelirin sırasıyla yıllık 59.1% ve 0.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 55.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 5.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

59.1%

Kazanç büyüme oranı

55.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	0.6%
Gelecekteki özkaynak getirisi	5.4%
Analist kapsamı	Good
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Recent updates

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 06

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Jul 23

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:PCRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	640	90	144	156	8
12/31/2025	646	55	157	181	8
12/31/2024	692	-5	189	133	8
9/30/2024	695	-91	194	204	N/A
6/30/2024	690	64	185	194	N/A
3/31/2024	682	70	173	185	N/A
12/31/2023	675	42	139	155	N/A
9/30/2023	666	7	130	149	N/A
6/30/2023	669	-5	127	147	N/A
3/31/2023	669	-10	105	134	N/A
12/31/2022	667	16	115	145	N/A
9/30/2022	654	21	93	126	N/A
6/30/2022	614	39	102	144	N/A
3/31/2022	580	38	104	144	N/A
12/31/2021	542	42	80	126	N/A
9/30/2021	513	62	98	149	N/A
6/30/2021	503	174	83	129	N/A
3/31/2021	443	148	39	83	N/A
12/31/2020	430	146	39	77	N/A
9/30/2020	421	126	28	56	N/A
6/30/2020	408	-10	13	35	N/A
3/31/2020	435	0	58	73	N/A
12/31/2019	421	-11	60	71	N/A
9/30/2019	394	2	58	66	N/A
6/30/2019	372	8	53	64	N/A
3/31/2019	354	7	44	55	N/A
12/31/2018	337	0	34	49	N/A
9/30/2018	321	-4	27	45	N/A
6/30/2018	305	-11	N/A	25	N/A
3/31/2018	292	-33	N/A	15	N/A
12/31/2017	287	-43	N/A	18	N/A
9/30/2017	280	-51	N/A	18	N/A
6/30/2017	281	-66	N/A	33	N/A
3/31/2017	280	-54	N/A	37	N/A
12/31/2016	276	-38	N/A	33	N/A
9/30/2016	273	-36	N/A	33	N/A
6/30/2016	267	-11	N/A	26	N/A
3/31/2016	256	-3	N/A	26	N/A
12/31/2015	249	2	N/A	28	N/A
9/30/2015	241	10	N/A	26	N/A
6/30/2015	231	4	N/A	29	N/A
3/31/2015	219	-1	N/A	30	N/A
12/31/2014	198	-14	N/A	27	N/A
9/30/2014	169	-31	N/A	6	N/A
6/30/2014	141	-43	N/A	-13	N/A
3/31/2014	111	-52	N/A	-34	N/A
12/31/2013	86	-64	N/A	-44	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PCRX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: PCRX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: PCRX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: PCRX şirketinin gelirinin (yıllık 0.6% ) US pazarından (yıllık 9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PCRX şirketinin gelirinin (yıllık 0.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PCRX 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 5.4 %).

Pacira BioSciences Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 46% to US$20.83

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Consensus EPS estimates fall by 21%

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Price target decreased by 9.5% to US$55.89

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

Recent updates

Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024

Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Investor sentiment improves as stock rises 15%

Pacira Biosciences, Inc. Announces Board Changes

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Investor sentiment deteriorates as stock falls 44%

CEO & Director recently bought US$100k worth of stock

Price target decreased by 46% to US$20.83

New major risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 20%

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy